Lifastuzumab (CAS: 1615697-16-9) is a humanized monoclonal antibody that targets NaPi2b, a protein overexpressed in cancers like non-small cell lung cancer (NSCLC) and ovarian cancer. It can be linked to monomethyl auristatin E (MMAE) to create the antibody-drug conjugate (ADC) lifastuzumab vedotin (DNIB0600A), which has anticancer effects.
Key Features:
- Target: Binds to NaPi2b, found in certain cancers.
- Mechanism: Conjugates with MMAE to form lifastuzumab vedotin, delivering cytotoxic agents to tumor cells.
- Therapeutic Potential: Tested for treating cancers with NaPi2b overexpression, like NSCLC and ovarian cancer.
Applications:
- Cancer Research: Develops ADCs for targeted cancer therapy.
- Therapeutic Development: Combines with MMAE to create lifastuzumab vedotin for cancer treatment.
Handling and Storage:
- Storage: Store at -20°C, away from light.
- Precautions: Use protective equipment during handling.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
